Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2011;66(4):657-62.
doi: 10.1590/s1807-59322011000400022.

Treatment of chronic periodontitis decreases serum prohepcidin levels in patients with chronic kidney disease

Eduardo Machado Vilela  1 , Jessica Amaral Bastos, Natalia Fernandes, Ana Paula Ferreira, Alfredo Chaoubah, Marcus Gomes Bastos
Affiliations
Controlled Clinical Trial

Treatment of chronic periodontitis decreases serum prohepcidin levels in patients with chronic kidney disease

Eduardo Machado Vilela et al. Clinics (Sao Paulo). 2011.

Abstract

Objective: To determine the impact of periodontal treatment on serum levels of prohepcidin (the prohormone of hepcidin) and systemic inflammation markers, as well as correlations among these markers, in patients with chronic periodontitis and chronic kidney disease who were not undergoing dialysis.

Methods: We included 56 chronic periodontitis patients, 36 with chronic kidney disease and 20 without systemic diseases and with normal renal function (control group). Chronic kidney disease was defined as suggested by the clinical practice guidelines in the National Kidney Foundation. Chronic periodontitis was defined through clinical attachment level and by probing pocket depth, according to the American Association of Periodontology. The inflammatory markers ultrasensitive C-reactive protein, interleukin-6, and prohepcidin were evaluated before and 3 months after periodontal treatment.

Results: The efficacy of periodontal treatment was confirmed by the improvement in clinical parameters of chronic periodontitis in the control and chronic kidney disease groups. Periodontal treatment resulted in significant reductions in ultrasensitive C-reactive protein, interleukin-6 and serum prohepcidin levels in both groups. Moreover, in multivariate linear regression, the reduction in prohepcidin after periodontal treatment was significantly and independently associated with interleukin-6 levels in the control group.

Conclusions: By inducing a decline in the systemic inflammatory response and a decrease in serum prohepcidin, successful periodontal treatment may represent an important means of ameliorating the inflammatory burden seen in patients with chronic kidney disease.

Trial registration: ISRCTN59866656.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of study participants.
See this image and copyright information in PMC

Comment in

  • Chronic periodontitis and serum levels of hepcidin and hemoglobin.
    Carvalho RC, Leite SA, Rodrigues VP, Pereira AF, Ferreira TC, Nascimento FR, Nascimento JR, Gomes-Filho IS, Bastos MG, Pereira AL. Carvalho RC, et al. Oral Dis. 2016 Jan;22(1):75-6. doi: 10.1111/odi.12373. Epub 2015 Oct 13. Oral Dis. 2016. PMID: 26389530 No abstract available.

References

    1. Abensur H, Bastos MG, Canziani MEF. Aspectos atuais da anemia na doença renal crônica. J Bras Nefrol. 2006;28:104–107.
    1. K/DOQI. National Kidney Foundation. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis. 2002;39:S46–S75.
    1. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–3. 10.1126/science.1104742 - DOI - PubMed
    1. Malyszko J, Malyszko JS, Hryszko T, Pawlak K, Mysliwiec M. Is hepcidin a link between anemia, inflammation and liver function in hemodialysed patients. Am J Nephrol. 2005;25:586–90. - PubMed
    1. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480:147–50. 10.1016/S0014-5793(00)01920-7 - DOI - PubMed

Publication types

Associated data